- Home
- WALD vs NGNE Comparison
WALD vs NGNE Comparison
Compare WALD & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WALD
- NGNE
- Stock Information
- Founded
- WALD 1988
- NGNE 2003
- Country
- WALD United States
- NGNE United States
- Employees
- WALD N/A
- NGNE N/A
- Industry
- WALD Package Goods/Cosmetics
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- WALD Consumer Discretionary
- NGNE Health Care
- Exchange
- WALD Nasdaq
- NGNE Nasdaq
- Market Cap
- WALD 306.3M
- NGNE 325.3M
- IPO Year
- WALD 2021
- NGNE N/A
- Fundamental
- Price
- WALD $1.56
- NGNE $18.48
- Analyst Decision
- WALD Strong Buy
- NGNE Strong Buy
- Analyst Count
- WALD 5
- NGNE 7
- Target Price
- WALD $4.96
- NGNE $41.86
- AVG Volume (30 Days)
- WALD 528.0K
- NGNE 110.1K
- Earning Date
- WALD 11-11-2025
- NGNE 08-11-2025
- Dividend Yield
- WALD N/A
- NGNE N/A
- EPS Growth
- WALD N/A
- NGNE N/A
- EPS
- WALD N/A
- NGNE N/A
- Revenue
- WALD $273,868,000.00
- NGNE N/A
- Revenue This Year
- WALD $10.37
- NGNE N/A
- Revenue Next Year
- WALD $14.37
- NGNE N/A
- P/E Ratio
- WALD N/A
- NGNE N/A
- Revenue Growth
- WALD 25.55
- NGNE N/A
- 52 Week Low
- WALD $1.50
- NGNE $6.88
- 52 Week High
- WALD $4.40
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- WALD 35.98
- NGNE 35.93
- Support Level
- WALD $1.50
- NGNE $19.59
- Resistance Level
- WALD $1.79
- NGNE $20.46
- Average True Range (ATR)
- WALD 0.16
- NGNE 1.23
- MACD
- WALD 0.00
- NGNE -0.20
- Stochastic Oscillator
- WALD 10.00
- NGNE 13.37
About WALD Waldencast plc
Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.